Center for Scientific Review; Notice of Closed Meetings, 89461 [2023-28531]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 247 / Wednesday, December 27, 2023 / Notices
Extramural Activities, NIDCD, NIH, 6001
Executive Blvd., Bethesda, MD 20892, 301–
496–8683, shimk@nidcd.nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; Chemical
Senses Fellowship Review.
Date: February 8, 2024.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Shiguang Yang, DVM,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, NIDCD, NIH, 6001
Executive Blvd., Room 8349, Bethesda, MD
20892, 301–496–8683, yangshi@
nidcd.nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; Voice
Speech and Language Fellowship Review.
Date: February 9, 2024.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Sonia Elena Nanescu,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, NIDCD, NIH, 6001
Executive Blvd., Suite 8300, Bethesda, MD
20892, (301) 496–8683, sonia.nanescu@
nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; Hearing
and Balance Fellowship Review.
Date: February 13, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Kausik Ray, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders, National Institutes of Health, 6001
Executive Blvd., Rockville, MD 20852, 301–
402–3587. rayk@nidcd.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: December 21, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–28572 Filed 12–26–23; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:00 Dec 26, 2023
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group;
Biobehavioral Medicine and Health
Outcomes Study Section.
Date: January 29–30, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mark A. Vosvick, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110,
Bethesda, MD 20892, (301) 402–4128,
mark.vosvick@nih.gov.
Name of Committee: Cell Biology
Integrated Review Group; Cellular Signaling
and Regulatory Systems Study Section.
Date: January 29–30, 2024.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: David Balasundaram,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189,
MSC 7840, Bethesda, MD 20892, 301–435–
1022, balasundaramd@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–OD–
23–051 Emergency Award: RADx-UP
Dissemination and Implementation (D&I)
Research on COVID–19 Testing Interventions
among Underserved and Vulnerable
Populations.
Date: January 31, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jessica Bellinger, Ph.D.,
Scientific Review Administrator, Center for
PO 00000
Frm 00100
Fmt 4703
Sfmt 4703
89461
Scientific of Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3158,
Bethesda, MD 20892, 301–827–4446,
bellingerjd@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 21, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–28531 Filed 12–26–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government Owned Inventions
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
directed to a T cell receptor (TCR) that
specifically targets the Kita-Kyushu
Lung Cancer Antigen 1 (KK–LC–1). This
TCR may be used to develop novel
immunotherapies against several
common and aggressive epithelial
cancers. It may also be possible to use
portions of the KK–LC–1 TCR in
chimeric proteins for cancer therapy
and/or for antigen detection assays. This
technology was discovered and is being
developed by the National Cancer
Institute (NCI). The NCI is currently
seeking a licensee and/or collaborator to
further develop this technology.
FOR FURTHER INFORMATION CONTACT:
Inquiries related to this licensing and
collaboration opportunity should be
directed to: Suna Gulay French,
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702; Telephone: (240) 276–5530;
Facsimile: (240) 276–5504; Email:
suna.gulay@nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished information related to this
invention.
SUPPLEMENTARY INFORMATION: The
following patent applications are
available for licensing and/or
collaboration under a Cooperative
Research and Development Agreement
(CRADA):
1. U.S. Provisional Application No.
62/327,529;
SUMMARY:
E:\FR\FM\27DEN1.SGM
27DEN1
]]>Agencies
[Federal Register Volume 88, Number 247 (Wednesday, December 27, 2023)]
[Notices]
[Page 89461]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-28531]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Risk, Prevention and Health Behavior
Integrated Review Group; Biobehavioral Medicine and Health Outcomes
Study Section.
Date: January 29-30, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mark A. Vosvick, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110, Bethesda, MD 20892, (301)
402-4128, [email protected].
Name of Committee: Cell Biology Integrated Review Group;
Cellular Signaling and Regulatory Systems Study Section.
Date: January 29-30, 2024.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David Balasundaram, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189, MSC 7840, Bethesda, MD
20892, 301-435-1022, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; RFA-OD-23-051 Emergency Award: RADx-UP Dissemination and
Implementation (D&I) Research on COVID-19 Testing Interventions
among Underserved and Vulnerable Populations.
Date: January 31, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jessica Bellinger, Ph.D., Scientific Review
Administrator, Center for Scientific of Review, National Institutes
of Health, 6701 Rockledge Drive, Room 3158, Bethesda, MD 20892, 301-
827-4446, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: December 21, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-28531 Filed 12-26-23; 8:45 am]
BILLING CODE 4140-01-P
